SELUTION4BTK Trial

April 27, 2026 updated by: M.A. Med Alliance S.A.

SELUTION SLR™ 014 BTK: A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Effectiveness of the SELUTION SLR™ 014 Drug Eluting Balloon in the Treatment of Below-the-Knee (BTK) Atherosclerotic Disease in Patients With Chronic Limb Threatening Ischemia (CLTI)

This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

376

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Austria
      • Graz, Austria, A-8036
        • Recruiting
        • LKH-Universitätsklinikum Graz
        • Principal Investigator:
          • Marianne Brodmann, MD
        • Contact:
  • France
      • Boulogne-Billancourt, France, 92100
        • Recruiting
        • Ambroise Paré Hospital
        • Principal Investigator:
          • Raphael Coscas, MD
        • Contact:
      • Paris, France, 75014
        • Recruiting
        • Hôpital St. Joseph
        • Principal Investigator:
          • Yann Goueffic, MD
        • Contact:
  • Germany
      • Arnsberg, Germany, 59759
        • Recruiting
        • Alexianer Klinikum Hochsauerland
        • Principal Investigator:
          • Michael Lichtenberg, MD
        • Contact:
      • Bad Krozingen, Germany, 79189
        • Recruiting
        • Universitäts-Herzzentrum Freiburg - Bad Krozingen
        • Principal Investigator:
          • Thomas Zeller, MD
        • Contact:
      • Buchholz, Germany, 21244
        • Recruiting
        • Krankenhaus Buchholz
        • Principal Investigator:
          • Klaus Hertting, MD
        • Contact:
      • Coburg, Germany, 96450
        • Recruiting
        • Sana Kliniken Oberfranken Coburg
        • Principal Investigator:
          • Marcus Thieme, MD
        • Contact:
      • Essen, Germany, 45147
        • Recruiting
        • University of Essen
        • Principal Investigator:
          • Christos Rammos, MD
        • Contact:
      • Tübingen, Germany
        • Recruiting
        • Universitätsklinikum Tübingen
        • Principal Investigator:
          • Jorg Schmehl
        • Contact:
  • Hong Kong
    • Pok Fu Lam
      • Hong Kong, Pok Fu Lam, Hong Kong
        • Recruiting
        • Queen Mary Hospital
        • Principal Investigator:
          • Yiu Che Chan, MD
        • Contact:
    • Shatin
      • Hong Kong, Shatin, Hong Kong
        • Recruiting
        • The Chinese University of Hong Kong
        • Principal Investigator:
          • Bryan Yan, MD
        • Contact:
  • Italy
      • Cotignola, Italy, 48033
        • Recruiting
        • UGC - Maria Cecilia Hospital
        • Principal Investigator:
          • Paolo Sbarzaglia, MD
        • Contact:
      • Genova, Italy, 16132
        • Terminated
        • Ospedale Policlinico San Martino
    • Verona
      • Peschiera del Garda, Verona, Italy, 37019
        • Recruiting
        • Ospedale Pederzoli
        • Contact:
        • Principal Investigator:
          • Bruno Migliara, MD
  • Netherlands
      • Nieuwegein, Netherlands, 3435 CM
        • Recruiting
        • St. Antonius Hospital
        • Principal Investigator:
          • Daniel van den Heuvel, MD
        • Contact:
  • New Zealand
      • Auckland, New Zealand, 1023
        • Recruiting
        • Auckland City Hospital
        • Principal Investigator:
          • Andrew Holden, MD
        • Contact:
  • Singapore
      • Singapore, Singapore, 169856
        • Recruiting
        • Singapore General Hospital
        • Principal Investigator:
          • Tze Tec Chong, MD
        • Contact:
  • Switzerland
      • Bern, Switzerland
        • Terminated
        • Inselspital Bern
  • United States
    • Arizona
      • Chandler, Arizona, United States, 85297
        • Recruiting
        • Chandler Regional Medical Center
        • Principal Investigator:
          • Dan Sraow, MD
        • Contact:
    • Arkansas
      • Jonesboro, Arkansas, United States, 72401
        • Recruiting
        • St. Bernards Medical Center
        • Principal Investigator:
          • Maximiliano Arroyo, MD
        • Contact:
      • Little Rock, Arkansas, United States, 72211
        • Terminated
        • Arkansas Heart Hospital
    • California
      • St. Helena, California, United States, 94574
        • Terminated
        • St. Helena Hospital
      • Torrance, California, United States, 90502
        • Recruiting
        • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
        • Principal Investigator:
          • Nikhil Kansal, MD
        • Contact:
    • Colorado
      • Thornton, Colorado, United States, 80023
        • Terminated
        • ClinRé
    • Connecticut
      • Darien, Connecticut, United States, 06820
        • Recruiting
        • Vascular Care Group
        • Principal Investigator:
          • Edward Arous, MD
        • Contact:
      • New Haven, Connecticut, United States, 06519
        • Recruiting
        • Yale University
        • Principal Investigator:
          • Carlos Mena, MD
        • Contact:
    • Florida
      • Gainesville, Florida, United States, 32605
        • Recruiting
        • The Cardiac and Vascular Institute Research Foundation
        • Principal Investigator:
          • Arthur Lee, MD
        • Contact:
      • Miami, Florida, United States, 33141
        • Recruiting
        • Palm Vascular Centers
        • Principal Investigator:
          • Robert Beasley, MD
        • Contact:
      • Winter Park, Florida, United States, 32792
        • Recruiting
        • Guardian Research Organization, LLC
        • Principal Investigator:
          • Ashish Gupta, MD
        • Contact:
    • Georgia
      • Thomasville, Georgia, United States, 31792
        • Terminated
        • Cardiovascular Consultants of South Georgia
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Recruiting
        • Rush University Medical Center
        • Principal Investigator:
          • Sreekumar Madassery, MD
        • Contact:
      • Park Ridge, Illinois, United States, 60068
        • Recruiting
        • Advocate Lutheran General Hospital
        • Principal Investigator:
          • Lewis Schwartz, MD
        • Contact:
    • Louisiana
      • Gray, Louisiana, United States, 70359
        • Recruiting
        • Cardiovascular Institute of the South
        • Principal Investigator:
          • Craig Walker, MD
        • Contact:
    • Maryland
      • Hyattsville, Maryland, United States, 20782
        • Recruiting
        • Medstar Health Research Institute
        • Principal Investigator:
          • Nelson Bernardo, MD
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Recruiting
        • Beth Israel Medical Center
        • Principal Investigator:
          • Mark Wyers, MD
        • Contact:
      • Worcester, Massachusetts, United States, 01655
        • Recruiting
        • University of Massachusetts Medical Center
        • Principal Investigator:
          • Douglas Jones, MD
        • Contact:
    • New York
      • New York, New York, United States, 10005
        • Recruiting
        • Sorin Medical Group
        • Principal Investigator:
          • Justin Ratcliffe, MD
        • Contact:
    • North Carolina
      • Raleigh, North Carolina, United States, 27607
        • Recruiting
        • NC Heart and Vascular Research, LLC
        • Principal Investigator:
          • Mohit Pasi, MD
        • Contact:
    • Ohio
      • Cleveland, Ohio, United States, 44106
        • Recruiting
        • University Hospitals Cleveland Medical Center
        • Principal Investigator:
          • Mehdi Shishehbor, MD
        • Contact:
      • Cleveland, Ohio, United States, 44195
        • Recruiting
        • Cleveland Clinic
        • Principal Investigator:
          • Ali Khalifeh, MD
        • Contact:
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73134
        • Recruiting
        • Hightower Clinical Research
        • Principal Investigator:
          • Jim Melton, MD
        • Contact:
    • Rhode Island
      • Providence, Rhode Island, United States, 02906
        • Recruiting
        • Miriam Hospital
        • Principal Investigator:
          • Peter Soukas, MD
        • Contact:
    • Tennessee
      • Nashville, Tennessee, United States, 37232
        • Recruiting
        • Vanderbilt University Medical Center
        • Principal Investigator:
          • Daniel Clair, MD
        • Contact:
      • Tullahoma, Tennessee, United States, 37388
        • Suspended
        • Tennessee Center for Clinical Trials
    • Texas
      • El Paso, Texas, United States, 79912
        • Recruiting
        • El Paso Cardiology
        • Principal Investigator:
          • Laiq Raja, MD
        • Contact:
      • Houston, Texas, United States, 77030
        • Recruiting
        • Baylor College of Medicine
        • Principal Investigator:
          • Jayer Chung, MD
        • Contact:
      • San Antonio, Texas, United States, 78229
        • Recruiting
        • Texas Cardiac and Vascular Institute San Antonio
        • Principal Investigator:
          • Jason Yoho, MD
        • Contact:
      • Tyler, Texas, United States, 75702
        • Recruiting
        • CHRISTUS Health
        • Principal Investigator:
          • Jeff Carr, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Clinical Inclusion Criteria:

  1. Subject age is ≥ 18 years or older depending on local regulations.
  2. Subject life expectancy is ≥ 1 year.
  3. Subject has documented chronic limb-threatening ischemia in the target limb with Rutherford classification category 4 or 5 and symptoms of > 2 weeks duration.
  4. Subject is willing and able to provide written informed consent and comply with study procedures and required follow-up evaluations.
  5. Female subjects of childbearing potential must be non-breastfeeding and have a negative pregnancy test ≤ 7 days before the procedure.

Angiographic Inclusion Criteria:

Subjects must meet all the following criteria to be enrolled in the trial:

  1. Target lesion(s) must be de novo or non-stented restenotic lesion(s) located within the BTK arteries distal to the tibial plateau and above the tibiotalar joint line. BTK arteries include the P3 segment of the popliteal artery, the tibio-peroneal trunk, peroneal artery, anterior tibial artery, and posterior tibial artery.
  2. BTK Target lesions cannot be contiguous with inflow lesions and at least 3 cm of normal artery should extend beyond the tibial plateau to ensure there is no overlap.
  3. Target lesions must have a diameter stenosis of ≥ 70% (including total occlusions) by visual estimate and must be indicated for PTA treatment.
  4. Target vessel reference diameter(s) are ≥ 2mm and ≤ 4mm. Note: the SELUTION SLR 014 DEB and the control PTA balloon size cannot exceed 4.0 mm.
  5. Target lesions must be confined to a single target vessel. NOTE: Subjects with other non-target BTK lesions in separate non-target vessels may be enrolled, provided that the non-target lesions have been successfully treated (residual stenosis ≤ 30% with no distal embolization or flow limiting ≥ Grade C dissection). NOTE: Any adjunctive therapies are permitted for the treatment of non-target BTK lesions, but no DEB or DES may be used.
  6. Any target lesion must be ≥ 30 mm in length and the total combined length of all target lesions must be ≤ 140 mm (total treatment length ≤ 150 mm allowing for 5 mm proximal and distal shoulder treatment). Note: All target lesions and all inflow lesions must be treatable by one or more SELUTION SLR 014/018 DEB(s) such that the total planned per-subject drug dose (calculated by summing the drug dose of all individual planned balloon sizes) would be ≤ 7069 μg. Note: A total treated segment length of ≤ 150 mm for BTK and ≤ 200 mm for inflow segment is acceptable irrespective of DEB balloon diameter.

  7. The tibial and pedal runoff distal to the target lesions must be patent OR the target vessel(s) must reconstitute above the ankle or display normal terminal branching as follows:

    1. If the target vessel is the P3 segment, any 1 of the 3 distal arteries must show a patent (≤ 50% stenosis by visual estimate) outflow.
    2. If the target vessel is the peroneal artery, the artery must demonstrate normal terminal branching.
    3. If the target vessel is the anterior tibial (AT) or posterior tibial (PT) artery, the artery must reconstitute ≥ 1 cm above the tibiotalar joint to provide an intact runoff vessel (AT: dorsalis pedis; PT: plantar artery).
    4. If the target vessel is the tibio-peroneal trunk, outflow for either the peroneal OR the posterior tibial artery must be patent (≤ 50% stenosis by visual estimate).
  8. Subjects is free of significant inflow vessel disease or any inflow disease has been successfully treated (see angiographic inclusion # 9). Significant inflow disease is defined as ≥ 50% stenosis by visual estimate. Inflow vessels include the ipsilateral common iliac, external iliac, common femoral, profunda femoris, superficial femoral or popliteal artery proximal (≥ 3 cm) to the tibial plateau. Note: If access site doesn't permit angiographic imaging of the common iliac and common femoral artery (CFA), then non-invasive imaging (CTA or MRA) must be provided to exclude presence of significant inflow disease. If non-invasive imaging is not possible, a DUS of the CFA with a multiphasic wave form excluding significant disease AND a palpable ipsilateral femoral pulse must be documented.
  9. Subjects with significant inflow disease (≥ 50% stenosis by visual estimate) must have documented successful treatment before randomizing the subject. Successful treatment of inflow disease is defined as ≤ 30% final residual stenosis and no distal embolization or flow-limiting > Grade C dissection. Note: Treatment of the common femoral and profunda femoris is not permitted. Inflow vessel treatment can be performed with any commercially available non-DCB or non-DES device; if DCB treatment is required, SELUTION SLR 018 must be used.
  10. The BTK target lesion preparation must be documented to be successful by angiography (≤ 30% residual stenosis and no distal embolization or flow-limiting ≥ Grade C dissection) before randomization. Note: Lesion preparation can include atherectomy (rotational, orbital, directional or laser), cutting, scoring, contoured balloons or intravascular lithotripsy and PTA only.

Clinical Exclusion Criteria:

Subjects will be excluded if any of the following criteria apply:

  1. Subject has extensive tissue loss (Rutherford category 6) extending above the trans metatarsal level, salvageable only with complex foot reconstruction or non-traditional trans metatarsal amputations. This includes subjects with:

    1. Osteomyelitis involving proximal to the metatarsal head(s)
    2. Any heel wound or wound with calcaneal bone involvement

    d) Wounds that would require flap coverage or complex wound management for large soft tissue defect e) Full-thickness wounds on the dorsum of the foot with exposed tendon or bone

  2. Subject has chronic renal insufficiency (dialysis dependent, or glomerular filtration rate [GFR] ≤ 30 ml/min/1.73 m2 within 30 days of index procedure) or has undergone renal transplantation.
  3. Subject has acute renal insufficiency confirmed by 50% increase of serum creatinine within 48 hours before procedure and/or decrease in urine output.
  4. Subject has acute limb ischemia with onset of index limb symptoms less than 2 weeks prior to index procedure.
  5. Subjects has wounds that are deemed to be neuropathic or non-ischemic in nature or any venous or mixed wounds.
  6. Subject has had prior major amputation of the ipsilateral extremity or planned major amputation of either leg.
  7. Target limb iliac or common femoral artery bypass within 6 weeks of index procedure.

  8. Prior (within 14 days) or planned (within 30 days) surgical or endovascular procedures. The following procedures are permitted:

    1. Target limb inflow treatment at the index procedure, provided it meets the criteria in Angiographic Inclusion Criteria #12
    2. Contralateral limb iliac artery treatment
    3. Diagnostic angiography
    4. Foot wound debridement
    5. Planned minor amputation of digit(s) at the phalangeal level
  9. Target lesion has undergone prior DCB within 1 year, or ANY prior DES or bare metal stent (BMS) treatment (no in-stent restenosis [ISR] treatment is permitted). Note: Prior stent is permitted if the target lesion is located ≥ 30 mm from the stent AND there is ≤ 30% in-stent diameter stenosis.
  10. Target lesion(s) requires treatment with alternative therapies such as thrombolysis, thrombus aspiration, stenting, cryoplasty, brachytherapy, or re-entry device. Note: The following adjunctive lesion preparation therapies are permitted: Atherectomy (rotational, orbital, directional or laser), cutting/scoring/contoured balloon, or intravascular lithotripsy.
  11. Target lesion requires treatment via pedal access or upper extremity access.
  12. Subject has undergone non-coronary artery treatment with any limus-based drug coated balloon (DCB) or DES or other device within 3 months prior to index procedure.
  13. Subject has known hypersensitivity or allergy to Sirolimus or other pharmacologic agents required for the procedure (such as contrast agent, heparin, bivalirudin) that cannot be adequately pre-treated.
  14. Subject has contraindication to antiplatelet therapy.
  15. Subject has experienced disabling stroke or ST-segment elevation myocardial infarction (STEMI) within 3 months of index procedure.
  16. Subject has acute coronary syndrome. Stabilized Acute Coronary Syndrome (ACS) is permitted.
  17. Subject has non-atherosclerotic disease of the target vessel (including aneurysmal disease and vasculitis) or Buerger's disease.
  18. Subject has hypercoagulable state or disorder, or coagulopathy, including platelet count ≤ 100,000 per microliter.
  19. Subject has systemic infection (White Blood Count [WBC] > 12,000 and febrile). [Note: Enrollment permitted after successful treatment of infection with resolution of leukocytosis and/or febrile state].
  20. Subject is known to be immune compromised (e.g., Human Immunodeficiency virus [HIV], Systemic Lupus Erythematosus [SLE]) or is receiving treatment with immune suppressive medications (NOTE: topical corticosteroids are permitted)
  21. Subject is receiving (or is scheduled to receive) cancer treatment with surgery or chemotherapy or radiation therapy or has metastatic malignancy. Note: local application of chemotherapeutic creams is allowed.
  22. Subject has New York Heart Association (NYHA) class IV congestive heart failure.
  23. Subject is bedridden.
  24. Subject has a body mass index (BMI) < 18.
  25. Subject is currently participating in another investigational drug or device study that has not completed primary endpoint follow-up.
  26. Subject has other anatomic, medical, social, or psychological conditions that in the investigator's opinion could limit the patient's ability to participate in the clinical study and/or comply with the follow-up requirements.

Angiographic Exclusion Criteria:

Subjects will be excluded if any of the following criteria apply:

  1. Presence of a previously placed stent in the target vessel(s), UNLESS the target lesion is located ≥ 30 mm from the stent AND there is ≤ 30% in-stent diameter stenosis.
  2. There is significant (> 50% diameter stenosis) inflow disease in the common femoral and profunda femoris arteries (inflow treatment of the common femoral and profunda femoris is not permitted).
  3. The target lesion could not be successfully pre-dilated (residual stenosis > 30%, distal embolization, or flow-limiting ≥ Grade C dissection after pre-dilatation).
  4. Intra-arterial thrombus, thromboembolism or atheroembolism in the index limb noted on initial diagnostic angiography or following treatment of inflow disease or pre-treatment of target lesion.
  5. Subject requires treatment of the tibial arteries distal to the tibiotalar joint line, or treatment of the pedal arteries. Angioplasty at or below the tibiotalar joint is not permitted.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SELUTION SLR™ DEB 014
Device: SELUTION SLR™ DEB 014
a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia
Active Comparator: Plain (Uncoated) Balloon Angioplasty (PTA)
Device: Plain (Uncoated) Balloon Angioplasty (PTA)
a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary Efficacy Endpoint
Time Frame: 6 months

Hierarchical composite efficacy endpoint determined by pair-wise comparisons among all subjects (Win Ratio method) according to the following pre-specified hierarchy of adverse outcomes:

  • Major (above-the-ankle) amputation
  • CD-TLR
  • Target lesion occlusion by angiography (if angiography is not available, the decision will be made on a secondary modality, in order of preference: computed tomography angiogram [CTA], magnetic resonance angiography [MRA] or DUS)
  • Transverse View Area Loss (TVAL%) by angiography.
6 months
Primary Safety Endpoint
Time Frame: 30 days
Freedom from the composite of MALE and all-cause perioperative death (POD). MALE is defined as major (above-the-ankle) amputation or major reintervention (new bypass graft, jump/ interposition graft revision, thrombectomy/thrombolysis) of the index limb.
30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Primary sustained clinical improvement
Time Frame: 1, 6, 12, 24, and 36 months
A secondary efficacy endpoint defined as freedom from target limb major amputation and CD-TLR AND increase in Rutherford category from baseline.
1, 6, 12, 24, and 36 months
Secondary sustained clinical improvement
Time Frame: 1, 6, 12, 24, and 36 months
A secondary efficacy endpoint defined as freedom from target limb major amputation AND increase in Rutherford category from baseline.
1, 6, 12, 24, and 36 months
Major amputation
Time Frame: 1, 6, 12, 24, and 36 months
A secondary efficacy endpoint defined as above-the-ankle amputation of the target limb.
1, 6, 12, 24, and 36 months
Amputation-free survival
Time Frame: 1, 6, 12, 24, and 36 months
A secondary efficacy endpoint defined as freedom from all-cause mortality and major amputation.
1, 6, 12, 24, and 36 months
Primary assisted patency
Time Frame: 1, 6, 12, 24, and 36 months

A secondary efficacy endpoint defined as freedom from ACL adjudicated occlusion on angiography or, if angiography is not available, by CTA, MRA or Duplex ultrasound core laboratory (DCL) adjudicated duplex ultrasound, irrespective of interventions for stenoses.

• Secondary patency, defined as freedom from permanent occlusion (occlusion at the last follow-up imaging) as determined by the ACL or DCL.
1, 6, 12, 24, and 36 months
Secondary patency
Time Frame: 1, 6, 12, 24, and 36 months
A secondary efficacy endpoint defined as freedom from permanent occlusion (occlusion at the last follow-up imaging) as determined by the ACL or DCL.
1, 6, 12, 24, and 36 months
CD-TLR
Time Frame: 1, 6, 12, 24, and 36 months
A secondary efficacy endpoint defined as re-intervention on target lesion(s) due to recurrent/persistent/worsening symptoms and the angiographic finding of ≥ 50% restenosis of target lesion by ACL measurement.
1, 6, 12, 24, and 36 months
Clinically driven (CD-TVR)
Time Frame: 1, 6, 12, 24, and 36 months
A secondary efficacy endpoint defined as re-intervention on target vessel due to recurrent/persistent/worsening symptoms and the angiographic finding of ≥ 50% restenosis of target vessel by ACL measurement.
1, 6, 12, 24, and 36 months
Rutherford category
Time Frame: 1, 6, 12, 24, and 36 months
A secondary efficacy endpoint defined as change in Rutherford category from baseline.
1, 6, 12, 24, and 36 months
ABI/TBI/Toe Pressure
Time Frame: 1, 6, 12, 24, and 36 months

A secondary efficacy endpoint defined as change in ankle brachial index (ABI), toe brachial index (TBI), and toe pressures from baseline.

• Change in Quality of Life (QOL) measures from baseline (EQ-5D and VascuQol instruments)
1, 6, 12, 24, and 36 months
Quality of Life (QOL) measures
Time Frame: 1, 6, 12, 24, and 36 months
A secondary efficacy endpoint defined as change in Quality of Life (QOL) measures from baseline (EQ-5D and VascuQol instruments).
1, 6, 12, 24, and 36 months
MALE
Time Frame: 1, 6, 12, 24, and 36 months
A secondary safety endpoint defined as the composite of major (above-the-ankle) amputation or major reintervention (new bypass graft, jump/ interposition graft revision, thrombectomy/thrombolysis) of the index limb.
1, 6, 12, 24, and 36 months
Major cardiovascular events
Time Frame: 1, 6, 12, 24, and 36 months

A secondary safety endpoint defined as the composite of cardiovascular death, myocardial infarction (MI), and stroke.

• All-cause mortality [evaluated at discharge, 1, 6, and 12 months and 2-5 years]
1, 6, 12, 24, and 36 months
All-cause mortality
Time Frame: 1, 6, 12, 24, and 36 months
1, 6, 12, 24, and 36 months
Device success
Time Frame: Post-procedure
A secondary performance endpoint defined as successful delivery, balloon inflation, deflation and retrieval of the intact investigational device.
Post-procedure
Procedural (technical) success
Time Frame: Post-procedure
A secondary performance endpoint defined as device success and residual diameter stenosis ≤ 30% on completion angiography by core lab assessment.
Post-procedure
Clinical success
Time Frame: Evaluated at discharge defined as immediately prior to hospital discharge from the index procedure or within 7 days, whichever occurs first
A secondary performance endpoint defined as procedural success without procedural complications (death, above-ankle target limb amputation, thrombosis of the target lesion or TLR) prior to discharge.
Evaluated at discharge defined as immediately prior to hospital discharge from the index procedure or within 7 days, whichever occurs first
Secondary Angiographic Imaging Measures
Time Frame: 6 months
  • Subsegmental analysis: proportion of segments with binary restenosis (DS > 50%)
  • Subsegmental analysis: Mean LLL of all segments; mean %DS of all segments.
  • TVAL%
6 months
Wound healing
Time Frame: 1, 6, 12, 24, and 36 months

A secondary wound measure defined as investigator reported status of each index wound in comparison to baseline.

Descriptive categories to be captured on case report forms (CRFs): 1) Improved 2) Unchanged 3) Worse 4) Healed/Complete Closure. Note: New wounds (appearing at any time after index procedure) are identified and tracked in similar fashion as index wounds, adopting the initial evaluation & images as "baseline" for future comparisons.
1, 6, 12, 24, and 36 months
Wound Ischemia, foot infection (WifI) Classification
Time Frame: 1, 6, 12, 24, and 36 months
A secondary wound measure defined as investigator-reported granular descriptors of Wound, Ischemia, and Foot Infection.
1, 6, 12, 24, and 36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.A. Med Alliance S.A.

Collaborators

NAMSA
Cordis US Corp.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 19, 2022

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

July 30, 2032

Study Registration Dates

First Submitted

September 14, 2021

First Submitted That Met QC Criteria

September 14, 2021

First Posted (Actual)

September 24, 2021

Study Record Updates

Last Update Posted (Actual)

April 28, 2026

Last Update Submitted That Met QC Criteria

April 27, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • S2021-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peripheral Arterial Disease

Clinical Trials on SELUTION SLR™ DEB 014

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe